Lucy Scientific Discovery Inc. (NASDAQ: LSDI) is a Nasdaq-listed company with holdings and operations in a variety of psychotropic businesses. The company holds a Controlled Drugs and Substances Dealer’s License granted by Health Canada’s Office of Controlled Substances. Lucy Scientific Discovery Inc. and its wholly-owned subsidiary, LSDI Manufacturing Inc., operate under Part J of the Food and Drug Regulations promulgated under the Food and Drugs Act (Canada). This specialized license authorizes LSDI to develop, sell, deliver, and manufacture pharmaceutical-grade active pharmaceutical ingredients (APIs) used in controlled substances and their raw material precursors. With a focus on pioneering innovative therapies for patients in need, Lucy Scientific Discovery Inc. is dedicated to advancing the understanding and applications of psychotropic medicines, improving mental health outcomes, and enhancing well-being for individuals worldwide.
Company profile
Ticker
LSDIF
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
LSDI Manufacturing Inc. • TerraCube International Inc. • 114474 BC Ltd. • Lucy Scientific Discovery (USA) Inc. • LSDI Retail Inc. • Lucy Therapeutic Discoveries Inc. • 1438430 BC Ltd. ...
LSDIF stock data
Latest filings (excl ownership)
25-NSE
Exchange delisting
6 Sep 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
1 Jul 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
28 May 24
NT 10-Q
Notice of late quarterly filing
15 May 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
9 May 24
8-K
Departure of Directors or Certain Officers
22 Apr 24
8-K
Termination of a Material Definitive Agreement
12 Mar 24
424B3
Prospectus supplement
1 Mar 24
EFFECT
Notice of effectiveness
28 Feb 24
8-K
Other Events
27 Feb 24
Latest ownership filings
Financial summary
| Quarter (USD) | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Jun 23 | |
|---|---|---|
| Revenue | ||
| Cost of revenue | ||
| Operating income | ||
| Operating margin | ||
| Net income | ||
| Net profit margin | ||
| Cash on hand | ||
| Change in cash | ||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 211.12 k | 211.12 k | 211.12 k | 211.12 k | 211.12 k | 211.12 k |
| Cash burn (monthly) | 8.83 k | (no burn) | 287.50 k | 967.44 k | (no burn) | 107.37 k |
| Cash used (since last report) | 89.76 k | n/a | 2.92 mm | 9.83 mm | n/a | 1.09 mm |
| Cash remaining | 121.36 k | n/a | -2.71 mm | -9.62 mm | n/a | -880.20 k |
| Runway (months of cash) | 13.7 | n/a | -9.4 | -9.9 | n/a | -8.2 |